VANI — Vivani Medical Share Price
- $69.27m
- $39.62m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.39 | ||
Price to Tang. Book | 2.39 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -55.8% | ||
Return on Equity | -75.65% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 3.38 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It is engaged in the development of the Company’s lead programs NPM-115 and NPM-119, is a GLP-1 implant candidates for the treatment of chronic weight management and patients with type 2 diabetes, respectively. Its other pipeline product candidates include NPM-139, and OKV-119. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. It operates through two segments: Biopharm Division and Neuromodulation Division. The Company’s implant technology, which it refers as NanoPortal, utilizes a space-efficient design that allows a miniaturized implant to provide many months of therapeutic delivery of potent molecules.
Directors
- Gregg Williams CHM (62)
- Scott Dunbar CEO (64)
- Edward Randolph VOP (63)
- Stephen Okland OTH (56)
- Alexandra Larson DRC (41)
- Jonathan McGuire DRC (58)
- Dean Baker IND (78)
- Aaron Mendelsohn IND (69)
- Matthew Pfeffer IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 22nd, 2003
- Public Since
- November 19th, 2014
- No. of Shareholders
- 110
- No. of Employees
- 44
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 54,978,465
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 1350 S. LOOP ROAD, ALAMEDA, 94502
- Web
- http://www.secondsight.com/
- Phone
- +1 8188335000
- Contact
- Brigid Makes
- Auditors
- BPM LLP
Upcoming Events for VANI
Q2 2024 Vivani Medical Inc Earnings Release
Q3 2024 Vivani Medical Inc Earnings Release
Similar to VANI
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
As of Today at 24:05 UTC, shares in Vivani Medical are trading at $1.25. This share price information is delayed by 15 minutes.
Shares in Vivani Medical last closed at $1.25 and the price had moved by -1.57% over the past 365 days. In terms of relative price strength the Vivani Medical share price has underperformed the S&P500 Index by -21.68% over the past year.
The overall consensus recommendation for Vivani Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Vivani Medical does not currently pay a dividend.
Vivani Medical does not currently pay a dividend.
Vivani Medical does not currently pay a dividend.
To buy shares in Vivani Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.25, shares in Vivani Medical had a market capitalisation of $68.72m.
Here are the trading details for Vivani Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VANI
Based on an overall assessment of its quality, value and momentum Vivani Medical is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vivani Medical is $8.00. That is 540% above the last closing price of $1.25.
Analysts covering Vivani Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.50 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vivani Medical. Over the past six months, its share price has underperformed the S&P500 Index by -4.19%.
As of the last closing price of $1.25, shares in Vivani Medical were trading -7.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vivani Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vivani Medical's management team is headed by:
- Gregg Williams - CHM
- Scott Dunbar - CEO
- Edward Randolph - VOP
- Stephen Okland - OTH
- Alexandra Larson - DRC
- Jonathan McGuire - DRC
- Dean Baker - IND
- Aaron Mendelsohn - IND
- Matthew Pfeffer - IND